Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD
Interview with Dhruv S. Kazi, MD, MSc, MS, author of Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.